口服泼尼松递减方案治疗中轴型脊柱关节炎的疗效:双盲随机对照试验(COBRA-AS研究)
该双盲随机对照试验纳入活动期中轴型脊柱关节炎(axSpA)患者,随机接受口服泼尼松递减方案或安慰剂治疗24周。结果显示泼尼松组BASDAI50应答率显著高于安慰剂组,但ASAS20/40应答及功能改善等关键次要终点无差异,且未研究对骨丢失的影响。
要点
- 泼尼松递减方案可使axSpA患者BASDAI50应答率提高至37.5%,安慰剂组为9.1%。
- ASAS20/40应答及BASFI、BAS-G、BASMI改善在两组间无显著差异。
- 泼尼松组前12周体重显著增加,但24周时无显著差异。
核心结论
- 小样本研究中口服泼尼松递减方案在axSpA达到主要终点BASDAI50有效,但功能改善等关键次要终点未达到。
研究设计与样本
- 概念验证性双盲随机对照试验,纳入活动性axSpA(BASDAI≥4)且以中轴病变为主(当前活动关节≤1个)并对NSAIDs应答不佳的患者。
- 泼尼松组32例,安慰剂组33例,按意向性分析。
主要发现
- 24周时泼尼松组BASDAI50应答12/32(37.5%),安慰剂组3/33(9.1%),差异28.4%(95%CI 7.9, 46.7)。
- ASAS20或ASAS40应答在两组间无差异。
- 24周时调整后ΔBASDAI和ΔASDAS-CRP组间有显著差异,但12周时无差异。
- 12周或24周时ΔBASFI、ΔBAS-G或ΔBASMI无显著差异。
- 泼尼松组前12周体重显著增加较安慰剂组为0.9(s.d. 0.4)kg,24周时无显著差异,未观察到严重不良事件。
关键数值与推荐
- 泼尼松递减方案:60、40、30、20、15、10 mg每日各1周,随后5 mg每日(或安慰剂)18周。
- 主要终点为24周时BASDAI50应答。
临床怎么用
- 对于活动性axSpA且对NSAIDs应答不佳的患者,短期口服泼尼松递减方案可能改善疾病活动度,但功能改善有限且需关注体重增加。
- 该方案对骨丢失的影响未研究,临床决策需权衡获益与风险。
局限性
- 样本量小(泼尼松组32例,安慰剂组33例)。
- 未研究对骨丢失的影响。
- 功能改善等关键次要终点未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy and safety of a step-down regimen of oral prednisolone over 24 weeks in patients of axial SpA (axSpA). METHODS: This proof-of-concept double-blind randomized controlled trial enrolled patients with active axSpA (BASDAI ≥4) having predominantly axial disease (≤1 active joint currently) and inadequate response to NSAIDs. They were randomized to receive either oral prednisolone (n = 32) or placebo (n = 33) at a dose of 60, 40, 30, 20, 15 and 10 mg daily for 1 week each, following which they received 5 mg prednisolone (or placebo) daily for 18 weeks. The primary endpoint was a 50% improvement in the BASDAI (BASDAI50) at week 24. Analysis was intention to treat. RESULTS: A BASDAI50 was achieved by 12 of 32 patients (37.5%) in the prednisolone arm and 3 of 33 patients (9.1%) in the placebo arm at 24 weeks [difference 28.4% (95% CI 7.9, 46.7)]. However, there was no difference in achieving a 20 or 40% improvement in the Assessment of SpondyloArthritis international Society response between the groups. Although there was a significant intergroup difference in adjusted ΔBASDAI and ΔAnkylosing Spondylitis Disease Activity Score with CRP at 24 weeks, there was no difference at 12 weeks. There was also no significant difference in ΔBASFI, ΔBAS-G or ΔBASMI at 12 or 24 weeks. No serious adverse events were noted. There was significant weight gain in the first 12 weeks in the prednisolone group vs placebo [0.9 (s.d. 0.4) kg], but not at 24 weeks. CONCLUSIONS: In this small study, oral prednisolone was efficacious in axSpA in achieving the primary outcome, but many crucial secondary outcomes such as functional improvement were not met. Its impact on bone loss was not studied.Trial registration: CTRI/2018/01/011342.
引用
- Mishra D, Dhir V, Naidu GSRSNK, et al. Efficacy of a step-down regimen of oral prednisolone in axial spondyloarthritis: result of a double-blind randomized controlled trial (COBRA-AS Study). Rheumatology (Oxford). 2021. PMID: 33159796. doi:10.1093/rheumatology/keaa685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。